BOSTON — Veteran Life Sciences entrepreneur Purnanad Sharma assumed the role of the 14th president of TiE Boston on July 1, 2024, for a two-year term, replacing Yash Shah.
In an exclusive Face-to-Face interview with INDIA New England News, Mr. Sarma talks about his vision for TiE Boston. To watch the full interview, please click here, or on the image below.
Mr. Sarma is Consulting CEO at GelMEDIX Inc, and until most recently, served as the President, CEO, and Board Member of Immunome (IMNM:NASDAQ), which he successfully led through an IPO in 2020, a large pharma transaction with $2 billion+ potential in January 2023, and a merger bringing in a seasoned new CEO and a $125 million concurrent investment in October 2023.
Mr. Sarma has over 30 years of experience in all aspects of the pharmaceutical and biotechnology business across multiple therapeutic platforms, and in companies of various sizes ranging from start-ups to large cap pharmaceutical companies including start-ups in the Boston life science ecosystem.
TiE Boston, the second oldest and second largest TiE chapter, currently has more than 225 charter members from various disciplines, such as technology, finance, life sciences, real estate and service industries.
